SEARCH

SEARCH BY CITATION

References

  • 1
    Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res2002; 55:307317.
  • 2
    Dharan NJ, Gubareva LV, Meyer JJ et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA2009; 301:10341041.
  • 3
    Cheng PK, To AP, Leung TW, Leung PC, Lee CW, Lim WW. Oseltamivir- and amantadine-resistant influenza virus A (H1N1). Emerg Infect Dis2010; 16:155156.
  • 4
    Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog2008; 4:e1000103.
  • 5
    Baz M, Abed Y, Simon P, Hamelin ME, Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis2010; 201:740745.
  • 6
    Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science2010; 328:12721275.
  • 7
    Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08. Emerg Infect Dis2009; 15:155162.
  • 8
    Lee N, Chan PK, Wong CK et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther2011; 16:237247.
  • 9
    Lee N, Choi KW, Chan PK et al. Outcomes of adults hospitalised with severe influenza. Thorax2010; 65:510515.
  • 10
    Ciancio BC, Meerhoff TJ, Kramarz P et al. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007–8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. Euro Surveill2009; 14:p11=19412.
  • 11
    Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AM. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA2009; 301:10421046.
  • 12
    Chor JS, Ngai KL, Goggins WB et al. Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys. BMJ2009; 339:b3391.
  • 13
    Kawai N, Ikematsu H, Hirotsu N et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007–2008 and 2008–2009 influenza seasons. Clin Infect Dis2009; 49:18281835.
  • 14
    Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther2012; 17:143157.
  • 15
    Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis2011; 203:610.
  • 16
    Hurt AC, Hardie K, Wilson NJ et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med2011; 365:25412542.